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ess under CC BY-NC-Abstract Topical 5-ﬂuorouracil (5-FU) is approved for the treatment of superﬁcial basal cell carcinoma and
actinic keratosis. However, 5-FU suffers from poor skin permeation. Microneedles have been successfully
applied to improve the skin permeability of small and large molecules, and even nanoparticles, by creating
micron-sized pores in the stratum corneum layer of the skin. In this report, the feasibility of using microneedles to
increase the skin permeability of 5-FU was tested. Using full thickness mouse skin mounted on Franz diffusion
apparatus, it was shown that the ﬂux of 5-FU through the skin was increased by up to 4.5-fold when the skin was
pretreated with microneedles (500 μm in length, 50 μm in base diameter). In a mouse model with B16-F10
mouse melanoma cells implanted in the subcutaneous space, the antitumor activity of a commercially available
5-FU topical cream (5%) was signiﬁcantly enhanced when the cream was applied on a skin area that was
pretreated with microneedles, as compared to when the cream was simply applied on a skin area, underneath
which the tumor cells were implanted, and without pretreatment of the skin with microneedles. Fluorouracil is not
approved for melanoma therapy, but the clinical efﬁcacy of topical 5-FU against tumors such as basal cell
carcinoma may be improved by integrating microneedle technology into the therapy.
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Microneedles and the skin permeability of 5-FU 951. Introduction
Fluorouracil (5-FU) is an antimetabolite that is used in the
treatment of various types of cancers, including breast, head and
neck, and colorectal cancer1,2. The ﬂuorinated pyrimidine analog
is available in topical formulations, which were approved by the
United States Food and Drug Administration (US FDA) to treat
actinic keratosis (non-cancerous) and superﬁcial basal cell carci-
noma (BCC)3,4. Approved topical products include 5-FU solutions
(e.g., Fluoroplex 1% 5-FU solution, Allergan, Inc., Irvine, CA,
USA), creams (e.g., Efudexs, Valeant Pharmaceuticals, Bridge-
water, NJ, USA), and a 0.5% microsphere-based cream (Caracs,
Valeant Pharmaceuticals). Other reported clinical applications of
topical 5-FU include the treatment of nail psoriasis3,5, cholestea-
toma6, lentigo maligna7 and some premalignant ophthalmic condi-
tions8. Topical treatment with 5-FU, when applicable, is usually
more preferred than surgical removal of affected lesions for cosmetic
reasons, especially for multiple lesions and/or facial lesions9.
Unfortunately, the skin permeability of topically applied 5-FU is
poor10–12, likely due to its hydrophilic nature (LogP¼0.89)13.
The use of topical 5-FU in BCC therapy is only limited to
superﬁcial BCC, and it is not recommended for invasive forms of
BCC4,14. This is based on a study by Mohs et al.14, who reported
that topical application of 5-FU in invasive BCCs can mislead
clinicians by showing superﬁcial improvement, while the deeper
parts of the cancerous lesions continue to grow unnoticed.
Several approaches to improve the skin permeation of topical
5-FU have been evaluated with different degrees of success. For
example, Paolino et al.11 described the formulation of 5-FU-loaded
bola-surfactant-based niosomes to improve the percutaneous
permeation and antitumor activity of 5-FU. The proposed nio-
somes exhibited an 8-fold increase in the percutaneous permeation
of 5-FU through human skin, as compared to 5-FU in an aqueous
solution. The 5-FU niosomes were signiﬁcantly more cytotoxic
against SKMEL-28 human melanoma cells in culture than 5-FU
solution, which was attributed to the improved cellular uptake of
5-FU in the niosomes11. Other researchers reported the use of
penetration enhancers such as azone, isopropyl myristate and
lauryl alcohol12, or the use of pharmaceutical formulation tech-
nologies (e.g., microemulsions10 and nanogels13), to increase the
percutaneous permeability of 5-FU. Physical methods to increase
the permeability of 5-FU have also been evaluated. For example,
Fang et al.15 studied the effect of a series of physical methods,
namely iontophoresis, electroporation, erbium:YAG (erbium:
yttrium–aluminum–garnet) laser and their combination, on the
permeability of 5-FU. Both iontophoresis and electroporation
signiﬁcantly enhanced the percutaneous permeability of 5-FU,
but the controlled removal of the stratum corneum by erbium:YAG
laser was most effective15, conﬁrming that it is the stratum
corneum that limits the skin permeability of 5-FU. However,
Meidan et al.16 found that ultrasound unexpectedly lowered the
permeability of 5-FU through whole rat skin; an effect that was
attributed to the back-diffusion of 5-FU to the ultrasonic coupling
gel ﬁlled in the donor compartment.
Microneedle technology had been successfully applied to
enhance the skin permeability of small molecules, macromolecules
and even nanoparticles by creating an array of micro-sized holes in
the stratum corneum of skin13,17–23. However, it remains unclear
whether it is feasible to increase the skin permeability of 5-FU by
pretreating skin with microneedles. In the present study, the
feasibility of using microneedles to improve the skin permeability
of 5-FU was tested in vitro using mouse skin mounted on a Franzdiffusion apparatus. In addition, the feasibility of using micro-
needles to improve the in vivo antitumor activity of 5-FU was
tested by comparing the ability of an FDA-approved topical 5-FU
cream in inhibiting the growth of subcutaneously implanted B16-
F10 tumors in mice. The 5-FU cream was applied on the mouse
skin area where the tumor cells were implanted with or without
pretreatment (of the skin area) with a microneedle roller. Topical
5-FU is not approved for melanoma treatment, but 5-FU was
reported to be effective against melanoma cells in culture and in
animal models19,20. The B16-F10 tumor cells are implanted
subcutaneously in mice, which allows indirect evaluation of the
in vivo permeation of 5-FU across mouse skin as well.2. Materials and methods
2.1. Materials
The Dermarollers microneedle roller was kindly provided by
Cynergy, LLC (Carson City, NV, USA). There are 192 needles
(500 mm in length, 50 mm in base diameter) on the roller. The
topical 5-FU cream (5%) was from Taro Pharmaceuticals
USA, Inc. (Hawthorne, NY, USA). Phosphate buffered saline
(PBS, pH 7.4), cell culture medium and antibiotics were from
Invitrogen (Life Technologies, Carlsbad, CA, USA). MTT (3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and 5-
FU were from Sigma-Aldrich (St. Louis, MO, USA).
2.2. In vitro cytotoxicity assay
B16-F10 murine melanoma cells were from the American Type
Culture Collection (Manassas, VA, USA) and maintained in
Dulbecco0s modiﬁed eagle medium (DMEM) with 10% (v/v) fetal
bovine serum, 10 U/mL of penicillin and 100 μg/mL of strepto-
mycin. Cells (2000/well) were seeded in 96-well plates and
incubated overnight at 37 1C, 5% CO2. Cells were then incubated
in the presence of various concentrations of 5-FU in PBS solution
(pH 7.4) for 24 h or 48 h. Cell viability was determined using an
MTT assay following the manufacturer0s instruction. The formed
formazan crystals were dissolved in 100 μL of dimethyl sulfoxide,
and the absorbance of the resultant solution was measured at
570 nm and 630 nm using a BioTek Synergy HT Multi-Mode
Microplate Reader (Winooski, VT, USA).
2.3. In vitro permeation of 5-FU in solution through mouse skin
In vitro permeation assay was completed as previously
described19. Full thickness dorsal skin from C57BL/6 mice was
used in the permeation study. Hair was carefully trimmed using an
electric clipper 24 h before the collection of the skin. The
harvested skins were stored at 20 1C and used within one
month. On the day when the permeability study was performed,
the skin was also treated with the Veets hair removal cream
(Reckitt Benckiser, Inc., UK) for 5 min and washed three times
with water. The skin was then mounted onto the Franz diffusion
cells (PermeGear, Inc., Hellertown, PA, USA) with the epidermis
side facing upward. The receiver compartment contained 5 mL of
PBS (pH 7.4, 10 mmol/L) and was maintained at 37 1C (Haake SC
100 Water Circulator, ThermoScientiﬁc, Wellington, NH, USA).
The diffusion area of the skin was 0.64 cm2. The donor compart-
ment was loaded with 400 μg of 5-FU in 400 mL of PBS (pH 7.4,
Figure 1 The amount of 5-FU in an aqueous solution diffused
through full thickness mouse skin treated () or not treated (○) with
microneedles as a function of time. Data shown are means7S.E.M
(n¼3). At all the time points tested, with the exception of 0 h, the
values between the microneedle-treated and -untreated groups are
signiﬁcantly different (Po0.05).
Figure 2 In vitro cytotoxicity of 5-FU against B16-F10 mouse
melanoma cells. Cells were incubated with various concentrations of
5-FU for 24 h () or 48 h (○), and cell viability was determined using
an MTT assay. Data shown are means (n¼6). Standard deviations are
not shown for clarity.
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test the effect of treatment with microneedles on the permeation of
5-FU through the skin, the skin samples were also treated with a
Dermarollers microneedle roller as previously described before it
was mounted onto the Franz diffusion cells21. Brieﬂy, the skin
sample was placed onto the ﬂat surface of a balance, and the
microneedle roller was rolled in 4 perpendicular lines over the skin
surface, 5 times each for a total of 20 times, with an applying
pressure of 600–800 g, which was constantly measured using the
balance. At pre-determined time points (1, 2, 3, 6 and 18 h),
samples (100 mL) were withdrawn from the receiver compartment
and immediately replenished with fresh medium. Samples were
then analyzed using HPLC. Chromatography was carried out with
an Agilent Technologies 1260 Inﬁnity HPLC workstation with an
Agilent ZORBAX Eclipse Plus C18 column (150 mm 4.6 mm,
5 μm) using a potassium phosphate buffer (40 mmol/L, pH 7.0) as
the mobile phase. The ﬂow rate was 0.5 mL/min. The detector
wavelength was 260 nm.
2.4. Animal study
Animal study was carried out following the US National Research
Council guide for the care and use of laboratory animals. The animal
protocol was approved by the Institutional Animal Care and Use
Committee at The University of Texas at Austin. Female C57BL/6
mice (8–10 weeks) were from Charles River Laboratories (Wilming-
ton, MA, USA). Hair in the lower dorsal skin of anesthetized mice
was trimmed using an electric clipper. B16-F10 murine melanoma
cells (100,000 cells per mouse) in 100 μL DMEM were injected
subcutaneously in the hair-trimmed area on day 0. On day 9, mice
were randomly grouped (5–6 mice per group) and treated as follows:
mice in the 5-FU cream group were treated with the 5% 5-FU cream
(100 mg of cream per mouse) on the area (about 1 cm 2 cm) where
the tumor cells were injected using a spatula, once daily for 8
consecutive days; mice in the MNþcream group were treated
similarly, except that the application area was pretreated with the
microneedle roller (MN); mice in the i.v. 5-FU group (positive
control) were injected with 5-FU in sterile PBS intravenously via the
tail vein (50 mg/kg body weight) on days 9 and 15. Negative control
groups include tumor-bearing mice that were left untreated or tumor-
bearing mice that were treated with the microneedle roller in the skin
area where the tumor cells were injected, but without further
treatment with 5-FU (i.e., MN group). To treat the mice with the
microneedle roller, mice were placed onto the ﬂat surface of a
balance, and the microneedle roller was rolled over the skin area
where the tumor cells were injected, 10 times parallel to the mouse
length, with an applying pressure of around 400 g, which was
measured using the balance. Tumor growth was monitored, and
tumor size measured using a digital caliper. Tumor volume was
calculated based on the following equation: tumor volume (mm3)¼
(lengthwidthwidth)/2. On the last day of the study (day 17),
mice were euthanized, and tumor tissues were collected and weighed.
2.5. Histology and immunohistochemistry
Tumor tissues were ﬁxed with a buffered formalin (10%) solution
for 48 h and then transferred to 70% ethanol until sections were
prepared, following parafﬁn embedding. The sections were stained
using hematoxylin–eosin (H & E) or an anti-CD31 antibody (an
angiogenesis marker, Abcam, Cambridge, MA, USA) in the
Histology and Tissue Processing Facility in the Dell PediatricResearch Institute at the University of Texas at Austin. Slides were
scanned, and images were taken using the ScanScope XT (Aperio
Technologies, Vista, CA, USA).
2.6. Statistical analyses
Statistical analyses were completed by performing analysis of
variance followed by Fisher0s protected least signiﬁcant difference
procedure. A P-value ofr0.05 (two-tail) was considered signiﬁcant.3. Results and discussion
Topical 5-FU products are available on the market for the
treatment of keratosis and superﬁcial BCC. The poor skin
Microneedles and the skin permeability of 5-FU 97permeation of 5-FU limits its application against various other
cancerous and non-cancerous conditions. Moreover, increasing the
skin permeability of 5-FU may also improve the clinical outcomes
of topical 5-FU in BCC therapy. Microneedles have been
successfully applied to increase the skin permeability of large
and small molecules, and even nanoparticles, by creating micro-
sized holes in the stratum corneum of skin17–21. The feasibility of
using microneedles to improve the skin permeability of 5-FU was
tested in the present study by pretreating skin with a microneedle
roller that has solid microneedles (500 μm in length, 50 μm in base
diameter) on it. The effect of pretreatment of mouse skin with
microneedles on the diffusion of 5-FU (in an aqueous solution)
through full thickness mouse skin (C57BL/6 mice) was initially
evaluated in vitro using a Franz diffusion apparatus. As expected,
the permeation of 5-FU through intact full thickness mouse skin
was limited, with a ﬂux of 8.9374.55 μg/cm2/h (Fig. 1).Figure 3 (A) The growth curves of B16-F10 tumors in C57BL/6 mice. (B
of tumors at the end of the study. (D) The changes in the body weight o
injected with B16-F10 tumor cells on day 0. Starting on day 9, mice were gr
consecutive days on the skin area where the tumor cells were injected. The a
with a microneedle roller before the application of the cream. As a positiv
5-FU) on day 9 and 15. Other controls included tumor-bearing mice left un
skin area where the tumor cells were injected (i.e., MN). The asterisks (n)
5-FU cream group are different on day 13, 15, and 17 (Po0.05). Data show
included in D for clarity (n¼5–6).Previously, Fang et al.15 reported a ﬂux value of 1.5–2 μg/cm2/h
(at pH 5.0) for the diffusion of 5-FU across full thickness nude
mouse skin. However, the permeability of 5-FU through mouse
skin that was pretreated with microneedles was signiﬁcantly
higher, with a ﬂux of 39.75718.50 μg/cm2/h, which is 4.5-fold
larger than the ﬂux of 5-FU through mouse skin that was not
pretreated with microneedles (Po0.05). Clearly, pretreatment of
mouse skin with solid microneedles signiﬁcantly increased the
permeability of 5-FU through the skin.
To test whether pretreatment of mouse skin with microneedles
can improve the antitumor activity of topical 5-FU by increasing
its skin permeability, the ability of a topical 5-FU cream to inhibit
the growth of mouse B16-F10 melanoma cells implanted sub-
cutaneously in the application area in mice was evaluated; the area
where the 5-FU cream was applied was pretreated with the
microneedle roller every time before the application of the 5-FU) Digital photograph of tumors at the end of the study. (C) The weights
f B16-F10 tumor-bearing mice. C57BL/6 mice were subcutaneously
ouped (n¼5–6) and topically treated with 5-FU cream (5%) daily for 8
pplication area was pretreated (MNþ5-FU cream) or not (5-FU cream)
e control, mice were intravenously injected with a 5-FU solution (i.v.
treated, or tumor-bearing mice treated with a microneedle roller in the
in A indicates that the values of the 5-FU cream group and the MNþ
n in A and C are mean7S.E.M (n¼5–6). Standard deviations are not
Y.W. Naguib et al.98cream. Although 5-FU is not approved for melanoma therapy, it
was previously shown to be cytotoxic against human and murine
melanoma cells13,22,23. Our own data also conﬁrmed that 5-FU
inhibited the growth of the B16-F10 mouse melanoma cells in
culture (Fig. 2). B16-F10 mouse melanoma cells were subcuta-
neously implanted in the rear dorsal area of female C57BL/6 mice.
When tumor sizes reached 20–40 mm3 (9 days following implan-
tation), mice were treated with the 5-FU cream (5%) topically on
the skin area where the tumor cells were implanted. As shown in
Fig. 3A, B16-F10 tumors grew aggressively if left untreated.
Topical treatment with 5-FU cream (without pretreatment of the
skin area with microneedles) signiﬁcantly inhibited the tumor
growth (Fig. 3A). However, the 5-FU cream became signiﬁcantly
more effective in inhibiting the tumor growth when the skin area
where the 5-FU cream was applied was pretreated with the
microneedle roller (Fig. 3A). At the end of the study, mice were
euthanized to collect tumor tissues (Fig. 3B). The average weight
of tumors in mice that were topically treated with the 5-FU cream
without pretreatment with microneedles was signiﬁcantly smaller
than in mice that were left untreated, but was signiﬁcantly larger
than in mice that were treated with microneedles before the
application of the 5-FU cream (Fig. 3C). In fact, the growth of
tumors in mice that were treated with the topical 5-FU cream
following pretreatment of the skin area with the microneedle roller
was completely inhibited (Fig. 3A–C). The experiment was
repeated with twice daily applications of 5-FU cream as well,
and similar results were obtained (data not shown). The antitumor
activity of the topical 5-FU following pretreatment (of the skin
area) with microneedles was not simply due to the mechanical
activity of applying the microneedle roller daily on the mouse skin
area where the tumor cells were subcutaneously injected, because
treatment with the microneedle roller alone without subsequent
application of the 5-FU cream did not show any signiﬁcant effect
on the growth of the B16-F10 tumors (Fig. 3A–C). The body
weights of the mice were also monitored during the treatment
period, and it was found that the weights of mice that were treated
with the 5-FU cream following pretreatment with microneedles,
once daily for 8 consecutive days, did not signiﬁcantly change
(Fig. 3D), suggesting that the practice of applying 5-FU cream on a
skin area pretreated with microneedles is potentially safe. Finally,
the tumor tissues were also collected from mice and examined
microscopically. H & E staining revealed that except in mice that
were treated with microneedles prior to the application of the 5-FUFigure 4 Representative images of tumor tissues after H&E staining (
(C: 10 , bar¼200 μm).cream (i.e., the MNþ5-FU cream group), tumors in all other groups
were large (Fig. 4A), with densely packed cells and scattered
necrotic areas (Fig. 4B). On the contrary, tumors in mice that were
treated with 5-FU cream after pretreatment with microneedles were
smaller (Fig. 4A), and the tumor cells were loosely distributed with
large intercellular spaces (Fig. 4B). Anti-CD31 staining (a maker
for angiogenesis) also revealed that the extent of CD31-positive
staining was signiﬁcantly less in tumors in mice in the MNþ5-FU
cream group than in tumors in mice from other groups (Fig. 4C).
Taken together, it is clear that the 5-FU cream was more
effective in inhibiting the growth of the B16-F10 tumor cells
subcutaneously implanted underneath the skin when it was applied
on a mouse skin area pretreated with microneedles than without
microneedle pretreatment (Fig. 3), likely because pretreatment
with microneedles enabled more 5-FU to permeate through the
skin and reach the tumor cells in the subcutaneous space. Data in
Fig. 1 clearly demonstrated that pretreatment of mouse skin with
microneedles signiﬁcantly increased the permeability of 5-FU
through the skin. As mentioned earlier, topical 5-FU is approved
by the US FDA for the treatment of superﬁcial BCC. BCC is
developed from basal cells in basement membrane layer in the skin
epidermis 24. The data generated in the present study with the B16-
F10 melanoma cells established in the subcutaneous space under-
neath the skin dermis layer may not accurately predict the effect of
topical 5-FU applied on a skin area pretreated with microneedles
on the growth of spontaneously developed BCC. However, in both
cases, the 5-FU applied topically onto the skin needs to ‘travel’
across the stratum corneum layer before it can reach the live
epidermis layer underneath the stratum corneum or the subcuta-
neous space. Data from previous studies showed that the stratum
corneum layer is rate-limiting in the percutaneous absorption of
5-FU15. In addition, microneedles0 ability to increase the skin
permeability of molecules is mainly attributed to the micro-pores
or holes created by them in the stratum corneum19,20. Therefore,
the ﬁnding that pretreatment of a skin area with microneedles
signiﬁcantly enhanced the antitumor activity of topical 5-FU
against the subcutaneously implanted mouse B16-F10 tumor cells
may be exploited to improve the efﬁcacy of topical 5-FU against
human BCC in clinics, especially considering that microneedle
rollers, including the one that was used in the present study,
are already used by humans for cosmetic purposes and dermatol-
ogy therapy to stimulate collagen and elastin production20,21,25.
Moreover, since the dermal permeability of 5-FU can beA: 2 , bar¼1 mm, B: 10 , bar¼200 μm) or anti-CD31 staining
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needles, it may become possible to evaluate this treatment strategy
for transdermal systemic delivery of 5-FU to treat invasive forms
of BCC or other cancers (e.g., breast, colorectal, pancreatic and
gastric cancers), against which intravenous 5-FU is currently
approved. Of course, comprehensive safety tests will have to be
completed to evaluate whether the microneedle technology can be
safely integrated into topical 5-FU therapy clinically. For example,
although microneedles such as the microneedle roller used in the
present study are already used by humans for cosmetic purposes
and dermatology therapy20,21,25, and topical 5-FU is approved by
the US FDA for the treatment of keratosis and superﬁcial BCC, it
remains unclear whether frequent applications of 5-FU on a
(human) skin area pretreated with microneedles will increase the
local and systemic toxicity of topical 5-FU. In addition, although
microneedles may not reach tumor cells when applied onto the
skin, it is unknown whether breaching the skin, or even the stratum
corneum alone, using the microneedles will negatively affect the
development of the tumors in the application area.4. Conclusions
In the present study, it was shown that the in vitro skin
permeability and in vivo antitumor activity of topical 5-FU were
signiﬁcantly enhanced when the application area was pretreated
with microneedles. Microneedle technology may be integrated into
topical 5-FU therapy to improve its efﬁcacy.
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